Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MLYS 
Mineralys Therapeutics, Inc. Common Stock (MLYS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: MLYS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $36.88
1 Year Target Price $36.88
| 6 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.87% | Avg. Invested days 26 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.01B USD | Price to earnings Ratio - | 1Y Target Price 36.88 |
Price to earnings Ratio - | 1Y Target Price 36.88 | ||
Volume (30-day avg) 8 | Beta -0.3 | 52 Weeks Range 8.24 - 18.38 | Updated Date 08/29/2025 |
52 Weeks Range 8.24 - 18.38 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.56 |
Earnings Date
Report Date 2025-08-12 | When - | Estimate -1.06 | Actual -0.66 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -38.8% | Return on Equity (TTM) -63.21% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 684096700 | Price to Sales(TTM) - |
Enterprise Value 684096700 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -7.41 | Shares Outstanding 66295200 | Shares Floating 44458876 |
Shares Outstanding 66295200 | Shares Floating 44458876 | ||
Percent Insiders 1.26 | Percent Institutions 112.97 |
Upturn AI SWOT
Mineralys Therapeutics, Inc. Common Stock
Company Overview
History and Background
Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for hypertension and kidney diseases. Founded in 2020, it went public in early 2023. It is developing a product candidate that targets aldosterone synthase.
Core Business Areas
- Drug Development: Focused on the development and commercialization of therapies for hypertension and kidney diseases.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of their lead product candidate, lorundrostat.
Leadership and Structure
The leadership team comprises experienced executives in drug development and commercialization, typically with a board of directors overseeing the company's strategic direction.
Top Products and Market Share
Key Offerings
- Lorundrostat: A selective aldosterone synthase inhibitor (ASI) being developed for the treatment of hypertension and kidney diseases. It is currently in Phase 2 clinical trials. There is no market share data since the drug is not approved yet. Competitors include established treatments for hypertension such as ACE inhibitors, ARBs, diuretics, and beta-blockers. Also, other companies are developing novel therapies for hypertension.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive, with companies focused on developing and commercializing new drugs. There is a significant need for new therapies for hypertension and kidney diseases.
Positioning
Mineralys is positioned as a company developing a novel mechanism of action for treating hypertension by selectively targeting aldosterone synthase. Their competitive advantage lies in the potential to provide a more targeted and effective treatment with fewer side effects compared to existing therapies.
Total Addressable Market (TAM)
The TAM for hypertension and kidney disease treatments is estimated to be in the billions of dollars. Mineralys is positioned to capture a significant share of this market if lorundrostat is approved.
Upturn SWOT Analysis
Strengths
- Novel mechanism of action (selective aldosterone synthase inhibition)
- Potential for improved efficacy and safety compared to existing treatments
- Experienced management team
- Strong intellectual property position
Weaknesses
- Clinical stage company with no approved products
- Dependence on the success of lorundrostat
- High risk of clinical trial failure
- Limited financial resources compared to larger pharmaceutical companies
Opportunities
- Large and growing market for hypertension and kidney disease treatments
- Potential for partnerships with larger pharmaceutical companies
- Expansion into new indications
- Positive clinical trial results
Threats
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Clinical trial failures
- Patent challenges
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- AZN
- NVS
- MRK
- PFE
Competitive Landscape
Mineralys competes with established pharmaceutical companies in the hypertension and kidney disease market. Its advantage is the novel mechanism of action; its disadvantage is its lack of established products and market presence.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company's early stage. Growth can be determined by looking at the stock price performance.
Future Projections: Future projections depend on the success of lorundrostat in clinical trials and its potential for regulatory approval. Analyst estimates vary based on their assessment of the drug's potential.
Recent Initiatives: Recent initiatives include advancing lorundrostat through clinical trials, presenting clinical data at scientific conferences, and securing financing.
Summary
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for hypertension, specifically lorundrostat. Its success is heavily reliant on clinical trials and regulatory approval. The company operates in a highly competitive market, and while its novel mechanism offers potential advantages, it also faces significant risks typical of drug development. The lack of revenue-generating products makes it a speculative investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Mineralys Therapeutics Inc. website
- SEC filings
- Analyst reports
- Company Press Releases
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Data is based on publicly available information and may not be entirely accurate or complete. Investing in clinical-stage biopharmaceutical companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Mineralys Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Radnor, PA, United States | ||
IPO Launch date 2023-02-10 | President, CEO & Director Mr. Jon Congleton | ||
Sector Healthcare | Industry Biotechnology | Full time employees 51 | Website https://mineralystx.com |
Full time employees 51 | Website https://mineralystx.com | ||
Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. The company's clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, and obstructive sleep apnea. It has initiated a Phase 2 trial for lorundrostat in hypertensive patients with stage 2 to 3b chronic kidney disease and a pivotal clinical program of lorundrostat for the treatment of uncontrolled or resistant hypertension. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. Mineralys Therapeutics, Inc. was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.